Objective: Cisplatin can induce severe renal toxicity. However, the degree and pattern of hydration that is most efficient at preventing it have scarcely been formally evaluated. We here performed a prospective feasibility study of cisplatin-based chemotherapy with short-term low-volume hydration in advanced lung cancer. Methods: Chemo-naïve patients with advanced lung cancer and reserving renal function who were suitable for cisplatin use (!60 mg/m 2 on Day 1) were eligible for this study. Two-and-a-half-liter hydration within 4.5 h was investigated. The primary end point was the proportion of patients who underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity in the first cycle. Results: A total of 46 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl and the median cisplatin dose on Day 1 was 80 mg/m 2 . In the first cycle, none of the patients developed Grade 2 or more creatinine toxicity, which met the primary endpoint. Four patients (9%) had Grade 1 toxicity, with a median worst creatinine score of 1.19 mg/dl, but it disappeared rapidly. Creatinine toxicity was influenced by several clinical factors, including the performance status. Ten patients (22%) needed extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 were able to undergo further cycles of treatment. Thirty-two (86%) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. Conclusions: This study demonstrated prospectively the feasibility of short-term low-volume hydration.
INTRODUCTION
Cisplatin-based chemotherapy is a mainstay for the treatment of advanced lung cancer (1 -3) . Indeed, although carboplatin, an analog of cisplatin with a milder toxicity profile, was also introduced for clinical use, randomized trials and meta-analysis showed that cisplatin-based chemotherapy was significantly superior to carboplatin-based chemotherapy in terms of response rate and survival in non-small-cell lung cancer (1) . In addition, cisplatin was shown to have a significant role in the treatment of small-cell lung cancer, whereas carboplatin is being used increasingly as an alternative chemotherapeutic agent (4, 5) . Thus, cisplatin still plays a pivotal role in the treatment of advanced lung cancer.
However, despite the detailed mechanism not being known, cisplatin can induce severe renal toxicity with widespread necrosis in the proximal tubules of the kidney (6) . Classically, !4 l hydration (standard hydration) on the day when cisplatin is administered has been applied to avoid toxicity, according to the regulation of the Japanese government. Its administration, however, is time consuming, which usually makes it difficult in the outpatient setting and reduces patients' quality of life. In contrast, in the USA and Europe, hydration with lower volumes is routinely performed in clinical practice. However, the feasibility of low-volume hydration has been scarcely and accurately evaluated in formal, prospective trials over the past three decades. Against this background, we here report a prospective feasibility study of cisplatin-based chemotherapy with short-term, low-volume hydration in advanced lung cancer.
PATIENTS AND METHODS

PATIENTS AND TREATMENT
The key inclusion criteria were as follows: age 75 years, performance status (PS) of 0 to 1, pathological diagnosis of lung cancer, Stage III or IV disease not amenable to curative survival or radiotherapy, no prior cytotoxic chemotherapy, except prior adjuvant chemotherapy completed !1 year before and appropriate for cisplatin-based chemotherapy on Day 1 (!60 mg/m 2 ) with reserved renal function, including a serum creatinine level below the institutional upper normal limit and a creatinine clearance rate of !60 ml/min) (Supplementary data, Table A1 ).
After a common antiemetic premedication and one other cytotoxic agents including pemetrexed and docetaxel, 1-h infusion of cisplatin dissolved in a total of 500 ml of normal saline solution was administered between the pre-and posthydration (500 ml of half saline solution each). Mannitol that could prevent cisplatin nephrotoxicities (7, 8) was infused just before the cisplatin administration (Supplementary data, Table A2 ). Patients were strongly requested to drink at least 1 l of water on Days 1 -3. Cisplatin-based chemotherapy was repeated every 3 or 4 weeks for up to four to six cycles unless disease progression or unacceptable toxicity was observed, or the patient refused further treatment. All patients received the first cycle of the therapy in the inpatient setting to facilitate thorough safety monitoring. They then continued the therapy at the outpatient clinic at our institute if no serious adverse events were observed. Definition of dose modification is listed in Supplementary data, Table A3 .
ASSESSMENT OF TOXICITY
All toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE; ver. 4.0). In this CTCAE version, two methods of assessment are documented regarding creatinine toxicity: one is based on the upper limit of the normal range (ULN) for serum creatinine at each institute (ULN-based) and the other on the pretreatment baseline creatinine score in each patient (baseline-based). The ULN at our institute is 1.1 for males and 0.8 for females. In this study, we used both of these methods (see the Statistical Considerations section).
ENDPOINTS
The primary endpoint was the proportion of patients who successfully underwent cisplatin-based chemotherapy without any Grade 2 or more renal toxicity (assessed by serum creatinine level) during the first cycle. Toxicity was checked once per week in the 30 days after the administration of cisplatin or until the day when the next cycle was initiated.
The secondary endpoints were response rate, other toxicities, rate of immediate hospitalization due to renal failure, overall survival and progression-free survival. One patient was not diagnosed with lung cancer, but with prostatic cancer with pulmonary metastases, after completion of the third cycle of cisplatin-based chemotherapy. As the main clinical interest in this study was the degree of renal toxicity following cisplatin administration, we included this case only for the toxicity assessment.
This study was conducted in compliance with the principles of the Declaration of Helsinki, and the protocol was approved by the Okayama University institutional review board. All patients gave written informed consent before entering the study.
CLINICAL TRIAL NUMBER
UMIN Registration Number 000004493.
STATISTICAL CONSIDERATIONS
This trial was designed to assess the feasibility of cisplatinbased chemotherapy with short-term, low-volume hydration, as determined by the proportion of patients who safely completed the first cycle of therapy without any ULN-based Grade 2 or more renal toxicity. Also CTCAE ver. 4.0 adapts a new, baseline-based creatinine toxicity grading system; however, since we did not know whether this new grading system had been formally validated, it was used in our study as an option. Safety was also assessed in subsequent cycles. A minimax design was used to determine whether there was sufficient evidence that the treatment completion rate was at least 90% (clinically feasible) versus at most 75% (clinically infeasible), accepting a false-positive rate (a) of 10% and a false-negative rate (b) of 10%. The threshold value of 75% was derived
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Short-term hydration in lung cancer from the previous report, showing a Grade 2 or more creatinine toxicity of 11.5-21.8% in the standard long-term high-volume hydration setting (9) .The estimated accrual number was 40 patients. This regimen was to be rejected when ,35 of the 40 cases successfully completed the first cycle. With an assumed 10% dropout rate, a total of 45 patients were needed. Overall survival was defined as the interval between the date of enrollment in this study and death or the last follow-up visit. All statistical analyses were conducted with STATA/SE version 11.0 software (College Station, TX, USA).
RESULTS
PATIENTS
A total of 46 patients were registered in this study. Demographics of the patients and tumors and details of baseline renal function are listed in Table 1 . Three patients were not followed up sufficiently during this defined period because they were soon moved to other hospitals to continue the second cycle (follow-up at 18, 20 and 25 days in their first cycle). During treatment at our institute, two of the three patients had no ULN-based and baseline-based Grade 1 or more creatinine toxicity, whereas the other patient developed baseline-based Grade 1 toxicity (maximal creatinine score of just 0.63 mg/dl) at Day 4. Toxicity returned to Grade 0 within 14 days.
TREATMENT DELIVERY
The details of cisplatin-based chemotherapy delivery are shown in Table 2 . The median cisplatin dose on Day 1 was 80 mg/m 2 (range 60 -80 mg/m 2 ) ( Table 2A) . The median total actual number of cycles administered at our institute was three, less than the designated number of cycles. This was mainly because of disease progression during treatment (14 patients), and no further follow-up in five patients who did not develop severe toxicities and were transferred to other hospitals to continue treatment (Table 2B and C). Four other patients discontinued the protocol therapy due to several toxicities, but not serious renal toxicity.
Ten (22%) of the 46 patients needed additional hydration during the first cycle, mainly due to gastrointestinal toxicity that was potentially related to cisplatin (Table 2D ). Of these, one developed baseline-based Grade 2 creatinine toxicity, which improved 3 days later to Grade 0 (baseline-and ULN-based). All 10 patients were able to receive further cycles of therapy (Supplementary data, Table A4 ).
Thirty-nine patients (85%) were assumed at the end of the first cycle to be able to undergo further treatment (Table 2E) . Among the 37 patients (two were transferred to other institutes and were censored), five received subsequent therapy again in an inpatient setting, because of moderate toxicities during the first cycle in three patients and the wishes of two patients. The remaining seven patients (15%) stopped the therapy, most of whom developed progressive disease (Table 2E) . One discontinued treatment because of liver toxicity.
RENAL TOXICITY
During the first cycle, the cumulative follow-up time of the 46 patients was 1239 days. None of the patients developed ULN-based Grade !2 creatinine toxicity during the cycle, whereas baseline-based Grade 2 toxicity was observed in two patients (4%) ( Table 3 ). This met the primary endpoint of this trial. Two of the 34 patients with baseline-based Grade 1 toxicity and two with baseline-based Grade 2 toxicity had creatinine scores exceeding the ULN (ULN-based Grade 1 toxicity). In these four patients, the median (range) worst creatinine score and median (range) time to develop the ULN-based Grade 1 toxicity were 1.19 mg/dl (1.11 -1.31 mg/dl) and 10 days (3 -13 days), respectively. The creatinine score Cr, creatinine; ECOG, Eastern Cooperative Oncology Group; Ad, adenocarcinoma; Sq, squamous cell carcinoma; Sm, small-cell carcinoma; EGFR, epidermal growth factor receptor; NA, not assessed; eGFR, estimated glomerular filtration rate; NAG, N-acetyl-b-D-glucosaminidase; B2-MG, b2-microglobulin; Na, sodium; K, potassium; Cl, chloride; Ca, calcium. a n ¼ 37. b n ¼ 38. c n ¼ 36. Administered at our institute 37
Outpatient setting 32
Inpatient setting 5
Continued 1118 Short-term hydration in lung cancer The ULN at our institute is 1.1 mg/dl for males and 0.8 mg/dl for females.
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returned to below the ULN in all four patients, with a median time for its recovery of 7 days (range 0 -21 days). One of the four patients required administration of extra hydration (registration no. 31; see Supplementary data, Table A4 ).
Regarding renal toxicity during all cycles, the cumulative follow-up time for its assessment in the 46 patients was 4498 days. Overall renal toxicity in all cycles was slightly worse than that in the first cycle, but the difference did not seem to be clinically significant (Table 3A) . Grade 2 or worse creatinine toxicity was observed in zero (ULN-based) and four patients (9%) (baseline-based), respectively (Table 3B ). Four of the 34 patients with baseline-based Grade 1 toxicity and 3 of 4 patients with baseline-based Grade 2 toxicity had creatinine scores exceeding the ULN, that is, ULN-based Grade 1 toxicity. The median (range) worst creatinine score and median (range) time to develop the ULN-based Grade 1 toxicity in these seven patients were 1.17 mg/dl (1.11-1.31 mg/dl) and 13 days (3-84 days), respectively. The creatinine score returned to below the ULN in all seven patients, with the median time for its recovery of 4 days (range 0-21 days). Figure 1A shows the time course in the creatinine score during the first cycle for all 46 patients. Cisplatin administration induced elevation of the creatinine score in 36 (78%) of the 46 patients (baseline-based Grade 1 or more toxicity); the other 10 patients exhibited no increase in the score during the cycle. The score decreased at the end of the cycle in most of the patients [35 (97%) of the 36 patients]. The score did not decrease at the end of the first cycle in the remaining patient (a male), but did not exceed the ULN ( 1.1 mg/dl).
TIME COURSE OF CREATININE SCORE
When all cycles were assessed (Fig. 1B) , a similar time trend was observed. Cisplatin administration induced elevation of the creatinine score in 38 (83%) of the 46 patients (baseline-based Grade 1 or more toxicity). However, the score decreased at the end of the final cycle in 35 (97%) of the 38 patients. In the remaining patients (two males and one female), the score remained within the normal limits ( 1.1 and 0.8 mg/dl for males and females, respectively) during all cycles.
CLINICAL FACTORS AND RENAL TOXICITY
Next, we investigated potential causal relationships between various clinical factors and creatinine toxicity in the first cycle (Table 4) . We here defined the outcome as ULN-based Grade 1 or worse creatinine toxicity, since there was no ULN-based Grade 2 or worse creatinine toxicity, which was the primary endpoint. No significant relationships were detected in this exploratory analysis. In contrast, when we used the following three parameters as outcomes: D(worst creatinine score minus baseline creatinine score), ratio of the worst creatinine score to the baseline creatinine score and baseline-based creatinine grade (!1 versus 0), creatinine toxicity was influenced by PS and pre-treatment urine calcium score (Table 4) .
SURVIVAL
All patients were assessable for survival analysis. The 1-year survival rate was 76.6% with 95% confidence interval of 60.6 -86.8%.
DISCUSSION
During the first cycle, none of the patients developed ULN-based Grade !2 creatinine toxicity. The primary endpoint was thus met. Four patients (9%) had ULN-based Grade 1 toxicity with a median worst creatinine score of 1.19 mg/dl, but the creatinine level returned to below the ULN with a median time for recovery of 7 days. Overall renal toxicity in all cycles was slightly worse than that in the first cycle, with Grades 2 or more and 1 toxicity in zero and seven patients (15%), respectively. Creatinine toxicity was influenced by PS and baseline urine calcium level. Ten patients (22%) required extra hydration during the first cycle, mainly due to gastrointestinal toxicity. However, all 10 patients were able to receive further cycles of therapy. Thirty-two (86%) of the 37 patients who were assumed to be able to undergo further treatment at our institute received it in an outpatient setting. 
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Short-term hydration in lung cancer While there has been traditionally general agreement that intensive hydration is important to decrease the risk of cisplatin nephrotoxicity, there have been few formal data from prospective trials on the optimal or minimum fluid volume required. Previous retrospective studies have shown that 2þ l of hydration per day was not associated with further improvement of renal toxicity due to cisplatin (6) . Additionally, 2 to 2.5 l of hydration allowed convenient outpatient administration of this drug with little risk of mild nephrotoxicity induced by cisplatin at a dose of 50 -120 mg/m 2 in a case study series (ULN-based Grade 2 or worse renal toxicity of around 5%) (10 -13) . In terms of renal toxicity, the current data from a small but formally designed prospective study of relatively short-term hydration with a total volume of 2.5 l were not inferior to those from classical retrospective studies (10 -12) , or studies that used a much higher hydration volume, ranging from 4 L per day, which are traditionally used as a Japanese standard (ULN-based Grade 2 or worse toxicity of 6 to 22%) (9, 14) .
During the first cycle, 10 patients (22%) needed additional, unplanned hydration on Days 4-8, mainly due to emesis (Supplementary data, Table A4 ), which led to renal toxicity (ULN-based Grade 1 toxicity) in one patient. Since (i) this renal toxicity was reversibly improved by 3 days of extra hydration administered at the time of occurrence of the event, that(ii) all 10 patients were able to receive further cycles of therapy, with cisplatin dose reduction in three patients and that (iii) only one of the 10 patients required extra hydration during subsequent cycles these does not necessarily indicate that the current hydration method is infeasible, despite the need for careful follow-up after cisplatin administration.
Notably, poorer PS was associated with creatinine toxicity (Table 4 ) when all three alternative outcomes were used (D (worst creatinine score minus baseline creatinine score), ratio of the worst creatinine score to baseline creatinine score, and baseline-based creatinine grade). Therefore, the acceptance of this assumption for the association is likely to be enhanced, although we recognize that this subgroup analysis represents only hypothesis generation. Patients with poor PS are believed to have an increased predisposition to a number of therapyrelated toxicities (15) (16) (17) (18) (19) (20) . Despite the lack of reports supporting this, patients with a worse PS might also be susceptible to adverse events associated with renal function. Furthermore, baseline urine calcium levels seemed to influence renal toxicity ( Table 4 ). Assuming that minerals including calcium are transported in the proximal tubule, which cisplatin can damage (6), further investigations to clarify the mechanisms underlying these associations are warranted.
This study had a number of limitations. Due to the small sample size and a potential patient selection bias, confirmation of the results in a multicenter large-scaled observational study based on the clinical practice is needed to ensure the generalizability of our data. Also, we did not investigate yet the influence of potential confounders including the history of diabetes B2-MG, b2-microglobulin. P ,0.05 for the BL creatinine score (1), for BL-based toxicity ( Ð ) and for three parameters, D (worst creatinine score minus BL creatinine score), ratio of worst creatinine score to BL creatinine and BL-based toxicity) (%). a The cut-off level was set as the median score.
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Short-term hydration in lung cancer mellitus on causal relationship and the effect of this short hydration schedule on antitumor activity, and therefore the true clinical significance of this schedule should be elucidated. Furthermore, there are no available data regarding oral hydration on Days 1 -3, preventing us from assessing accurately how much its substantial impact on renal protection was.
In conclusion, we prospectively reappraised the feasibility of short-term low-volume hydration when administering cisplatin, an old but still important agent for the treatment of advanced lung cancer.
Supplementary data
Supplementary data are available at http://www.jjco.oxfordjournals.org.
